Yun Yan - OBI Pharma Director
| 4174 Stock | TWD 60.80 1.00 1.62% |
Insider
Yun Yan is Director of OBI Pharma since 2020.
| Tenure | 4 years |
| Phone | 886 2 2655 8799 |
| Web | https://www.obipharma.com |
OBI Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2189) % which means that it has lost $0.2189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3367) %, meaning that it generated substantial loss on money invested by shareholders. OBI Pharma's management efficiency ratios could be used to measure how well OBI Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| ShuFen Huang | TTY Biopharm Co | N/A | |
| Allen Chu | TTY Biopharm Co | N/A | |
| LanBo Chen | TaiMed Biologics | N/A | |
| TaiHorng Young | TaiMed Biologics | N/A | |
| YungMin Chiang | TTY Biopharm Co | N/A | |
| GwoFong Lin | TaiMed Biologics | N/A | |
| SiYuan Yang | TTY Biopharm Co | N/A | |
| Wenlii Lin | Medigen Biotechnology | N/A | |
| Qiankun Lin | TaiMed Biologics | N/A | |
| IngWen Tsai | TaiMed Biologics | N/A | |
| ShuWen Wang | TTY Biopharm Co | N/A | |
| ShiChung Chang | Medigen Biotechnology | 64 | |
| KuoChiang Chang | TTY Biopharm Co | N/A | |
| David MD | TaiMed Biologics | 70 | |
| JenYang Chang | TTY Biopharm Co | N/A | |
| Hui Zheng | TaiMed Biologics | N/A | |
| TienChieh Lee | TaiMed Biologics | N/A | |
| ChingLan Hou | TTY Biopharm Co | N/A | |
| WeiYing Yin | TTY Biopharm Co | N/A | |
Management Performance
| Return On Equity | -0.34 | |||
| Return On Asset | -0.22 |
OBI Pharma Leadership Team
Elected by the shareholders, the OBI Pharma's board of directors comprises two types of representatives: OBI Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OBI. The board's role is to monitor OBI Pharma's management team and ensure that shareholders' interests are well served. OBI Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OBI Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Huang, General Manager | ||
| Jerry Fong, Independent Director | ||
| Sophia Lee, Deputy General Manager-Statistic & Biometrics Division | ||
| ChengDer Yu, Chief Research and Development Officer | ||
| JiannShiun Lai, Deputy General Manager of Research-R&D Division | ||
| LungYeh Cho, Director | ||
| Wayne MD, Chief Officer | ||
| Kevin Poulos, Chief USA | ||
| Colin Kao, Senior Manager of Finance Division | ||
| ChengEn Tsai, Deputy General Manager-Medical Affairs & Clinical Research and Development | ||
| FACP FACP, Ex Director | ||
| Sharon Lee, Director PR | ||
| Victoria Lin, Chief Legal Officer | ||
| PoJen Chang, Director Admin | ||
| Michael Chang, Chairman of the Board, Chief Executive Officer | ||
| Taychang Wang, Independent Director | ||
| YuNan Shih, Deputy General Manager-Quality Assurance | ||
| ChiChuan Chen, CFO Director | ||
| Yun Yan, Director | ||
| ChungMing Chang, Independent Director | ||
| Mitchell MS, Chief USA | ||
| Frank Chen, Chief Financial Officer, Head of Finance, Director | ||
| Tamon Tseng, Vice Chairman of the Board | ||
| MingTien Lai, Chief Scientific Officer, Executive Deputy General Manager-R&D Division |
OBI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OBI Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.34 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (311.15) % | |||
| Current Valuation | 12.29 B | |||
| Shares Outstanding | 228.95 M | |||
| Shares Owned By Insiders | 36.77 % | |||
| Shares Owned By Institutions | 5.00 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 2,517 X | |||
| Revenue | 18.77 M |
Pair Trading with OBI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OBI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OBI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with OBI Stock
Moving against OBI Stock
| 0.73 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.73 | 0057 | Fubon MSCI Taiwan | PairCorr |
| 0.72 | 1449 | Chia Her Industrial Split | PairCorr |
| 0.69 | 4162 | PharmaEngine | PairCorr |
| 0.62 | 2609 | Yang Ming Marine | PairCorr |
The ability to find closely correlated positions to OBI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OBI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OBI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OBI Pharma to buy it.
The correlation of OBI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OBI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OBI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OBI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for OBI Stock Analysis
When running OBI Pharma's price analysis, check to measure OBI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OBI Pharma is operating at the current time. Most of OBI Pharma's value examination focuses on studying past and present price action to predict the probability of OBI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OBI Pharma's price. Additionally, you may evaluate how the addition of OBI Pharma to your portfolios can decrease your overall portfolio volatility.